Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
7.4
5.2
Journals
Cancers
Special Issues
Lymphocyte Migration in Solid Tumors
share announcement

Lymphocyte Migration in Solid Tumors

A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Molecular Cancer Biology".

Deadline for manuscript submissions: closed (31 December 2020) | Viewed by 8320

Special Issue Editor

Dr. Andreas Lundqvist

E-Mail Website
Guest Editor
Department of Oncology-Pathology, Karolinska Institutet, S-17164 Stockholm, Sweden
Interests: immunology; immunotherapy; cytokines; natural killer cells; tumor microenvironment

Special Issue Information

Dear Colleagues,

Several studies have provided evidence that the frequency of tumor-infiltrating T and NK cells is associated with a good prognosis and potentially even predicts response to therapy in patients with solid tumors. The migration of lymphocytes is governed by chemokines, which consist of small secreted polypeptides. Attempts to modulate the tumor microenvironment to produce chemokines to attract T and NK cells or the modulation of ex vivo expanded lymphocytes to express chemokine receptors have provided evidence of increased lymphocyte infiltration in solid tumors. This Special Issue focuses on several aspects to improve lymphocyte migration into solid tumors. Specific topics include but are not limited to manipulation of T and NK cells to express chemokine receptors, manipulation of the tumor microenvironment to attract T and NK cells, and cross-talk with tissue-resident cells to augment tumor infiltration of T and NK cells.

Dr. Andreas Lundqvist
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • lymphocytes
  • chemokines
  • migration
  • cancer

Published Papers (2 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

Jump to: Review

16 pages, 3303 KiB  
Article
RNA-Seq Analysis Reveals CCR5 as a Key Target for CRISPR Gene Editing to Regulate In Vivo NK Cell Trafficking
by Emily R. Levy, Joseph A. Clara, Robert N. Reger, David S. J. Allan and Richard W. Childs
Cancers 2021, 13(4), 872; https://doi.org/10.3390/cancers13040872 - 19 Feb 2021
Cited by 16 | Viewed by 3703
Abstract
A growing number of natural killer (NK) cell-based immunotherapy trials utilize ex vivo expansion to grow and activate allogenic and autologous NK cells prior to administration to patients with malignancies. Recent data in both murine and macaque models have shown that adoptively infused [...] Read more.
A growing number of natural killer (NK) cell-based immunotherapy trials utilize ex vivo expansion to grow and activate allogenic and autologous NK cells prior to administration to patients with malignancies. Recent data in both murine and macaque models have shown that adoptively infused ex vivo expanded NK cells have extensive trafficking into liver tissue, with relatively low levels of homing to other sites where tumors often reside, such as the bone marrow or lymph nodes. Here, we evaluated gene and surface expression of molecules involved in cellular chemotaxis in freshly isolated human NK cells compared with NK cells expanded ex vivo using two different feeder cells lines: Epstein-Barr virus (EBV)-transformed lymphoblastoid cell lines (LCLs) or K562 cells with membrane-bound (mb) 4-1BB ligand and interleukin (IL)-21. Expanded NK cells had altered expression in a number of genes that encode chemotactic ligands and chemotactic receptors that impact chemoattraction and chemotaxis. Most notably, we observed drastic downregulation of C-X-C chemokine receptor type 4 (CXCR4) and upregulation of C-C chemokine receptor type 5 (CCR5) transcription and phenotypic expression. clustered regularly interspaced short palindromic repeats (CRISPR) gene editing of CCR5 in expanded NK cells reduced cell trafficking into liver tissue and increased NK cell presence in the circulation following infusion into immunodeficient mice. The findings reported here show that ex vivo expansion alters multiple factors that govern NK cell homing and define a novel approach using CRISPR gene editing that reduces sequestration of NK cells by the liver. Full article
(This article belongs to the Special Issue Lymphocyte Migration in Solid Tumors)
►▼ Show Figures

Graphical abstract

Review

Jump to: Research

22 pages, 986 KiB  
Review
Immunotherapy and Its Development for Gynecological (Ovarian, Endometrial and Cervical) Tumors: From Immune Checkpoint Inhibitors to Chimeric Antigen Receptor (CAR)-T Cell Therapy
by Giuseppe Schepisi, Chiara Casadei, Ilaria Toma, Giulia Poti, Maria Laura Iaia, Alberto Farolfi, Vincenza Conteduca, Cristian Lolli, Giorgia Ravaglia, Nicole Brighi, Amelia Altavilla, Giovanni Martinelli and Ugo De Giorgi
Cancers 2021, 13(4), 840; https://doi.org/10.3390/cancers13040840 - 17 Feb 2021
Cited by 20 | Viewed by 3709
Abstract
Gynecological tumors are malignancies with both high morbidity and mortality. To date, only a few chemotherapeutic agents have shown efficacy against these cancer types (only ovarian cancer responds to several agents, especially platinum-based combinations). Within this context, the discovery of immune checkpoint inhibitors [...] Read more.
Gynecological tumors are malignancies with both high morbidity and mortality. To date, only a few chemotherapeutic agents have shown efficacy against these cancer types (only ovarian cancer responds to several agents, especially platinum-based combinations). Within this context, the discovery of immune checkpoint inhibitors has led to numerous clinical studies being carried out that have also demonstrated their activity in these cancer types. More recently, following the development of chimeric antigen receptor (CAR)-T cell therapy in hematological malignancies, this strategy was also tested in solid tumors, including gynecological cancers. In this article, we focus on the molecular basis of gynecological tumors that makes them potential candidates for immunotherapy. We also provide an overview of the main immunotherapy studies divided by tumor type and report on CAR technology and the studies currently underway in the area of gynecological malignancies. Full article
(This article belongs to the Special Issue Lymphocyte Migration in Solid Tumors)
►▼ Show Figures

Graphical abstract

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2
Back to TopTop